Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis
Cardiac fibrosis is a major hallmark of cardiac diseases. For evaluation of cardiac fibrosis, the development of highly specific and preferably noninvasive methods is desired. Our aim was to evaluate CNA35, a protein known to specifically bind to collagen, as a specific marker of cardiac fibrosis. F...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-12-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2014.00036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850081391532834816 |
|---|---|
| author | Sanne de Jong Lars B. van Middendorp Robin H.A. Hermans Jacques M.T. de Bakker Marti F.A. Bierhuizen Frits W. Prinzen Harold V.M. van Rijen Mario Losen Marc A. Vos Marc A.M.J. van Zandvoort |
| author_facet | Sanne de Jong Lars B. van Middendorp Robin H.A. Hermans Jacques M.T. de Bakker Marti F.A. Bierhuizen Frits W. Prinzen Harold V.M. van Rijen Mario Losen Marc A. Vos Marc A.M.J. van Zandvoort |
| author_sort | Sanne de Jong |
| collection | DOAJ |
| description | Cardiac fibrosis is a major hallmark of cardiac diseases. For evaluation of cardiac fibrosis, the development of highly specific and preferably noninvasive methods is desired. Our aim was to evaluate CNA35, a protein known to specifically bind to collagen, as a specific marker of cardiac fibrosis. Fluorescently labeled CNA35 was applied ex vivo on tissue sections of fibrotic rat, mouse, and canine myocardium. After quantification of CNA35, sections were examined with picrosirius red (PSR) and compared to CNA35. Furthermore, fluorescently labeled CNA35 was administered in vivo in mice. Hearts were isolated, and CNA35 labeling was examined in tissue sections. Serial sections were histologically examined with PSR. Ex vivo application of CNA35 showed specific binding to collagen and a high correlation with PSR (Pearson r = .86 for mice/rats and r = .98 for canine; both p < .001). After in vivo administration, CNA35 labeling was observed around individual cardiomyocytes, indicating its ability to penetrate cardiac endothelium. High correlation was observed between CNA35 and PSR ( r = .91, p < .001). CNA35 specifically binds to cardiac collagen and can cross the endothelial barrier. Therefore, labeled CNA35 is useful to specifically detect collagen both ex vivo and in vivo and potentially can be converted to a noninvasive method to detect cardiac fibrosis. |
| format | Article |
| id | doaj-art-a55eeeac91b44310b10638cc145d151f |
| institution | DOAJ |
| issn | 1536-0121 |
| language | English |
| publishDate | 2014-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-a55eeeac91b44310b10638cc145d151f2025-08-20T02:44:43ZengSAGE PublishingMolecular Imaging1536-01212014-12-011310.2310/7290.2014.0003610.2310_7290.2014.00036Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac FibrosisSanne de JongLars B. van MiddendorpRobin H.A. HermansJacques M.T. de BakkerMarti F.A. BierhuizenFrits W. PrinzenHarold V.M. van RijenMario LosenMarc A. VosMarc A.M.J. van ZandvoortCardiac fibrosis is a major hallmark of cardiac diseases. For evaluation of cardiac fibrosis, the development of highly specific and preferably noninvasive methods is desired. Our aim was to evaluate CNA35, a protein known to specifically bind to collagen, as a specific marker of cardiac fibrosis. Fluorescently labeled CNA35 was applied ex vivo on tissue sections of fibrotic rat, mouse, and canine myocardium. After quantification of CNA35, sections were examined with picrosirius red (PSR) and compared to CNA35. Furthermore, fluorescently labeled CNA35 was administered in vivo in mice. Hearts were isolated, and CNA35 labeling was examined in tissue sections. Serial sections were histologically examined with PSR. Ex vivo application of CNA35 showed specific binding to collagen and a high correlation with PSR (Pearson r = .86 for mice/rats and r = .98 for canine; both p < .001). After in vivo administration, CNA35 labeling was observed around individual cardiomyocytes, indicating its ability to penetrate cardiac endothelium. High correlation was observed between CNA35 and PSR ( r = .91, p < .001). CNA35 specifically binds to cardiac collagen and can cross the endothelial barrier. Therefore, labeled CNA35 is useful to specifically detect collagen both ex vivo and in vivo and potentially can be converted to a noninvasive method to detect cardiac fibrosis.https://doi.org/10.2310/7290.2014.00036 |
| spellingShingle | Sanne de Jong Lars B. van Middendorp Robin H.A. Hermans Jacques M.T. de Bakker Marti F.A. Bierhuizen Frits W. Prinzen Harold V.M. van Rijen Mario Losen Marc A. Vos Marc A.M.J. van Zandvoort Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis Molecular Imaging |
| title | Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis |
| title_full | Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis |
| title_fullStr | Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis |
| title_full_unstemmed | Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis |
| title_short | Ex Vivo and in Vivo Administration of Fluorescent CNA35 Specifically Marks Cardiac Fibrosis |
| title_sort | ex vivo and in vivo administration of fluorescent cna35 specifically marks cardiac fibrosis |
| url | https://doi.org/10.2310/7290.2014.00036 |
| work_keys_str_mv | AT sannedejong exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT larsbvanmiddendorp exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT robinhahermans exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT jacquesmtdebakker exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT martifabierhuizen exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT fritswprinzen exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT haroldvmvanrijen exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT mariolosen exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT marcavos exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis AT marcamjvanzandvoort exvivoandinvivoadministrationoffluorescentcna35specificallymarkscardiacfibrosis |